Passage of a drug across a biomembrane, such as a cell bilayer, vascular endothelium and bowel epithelium, the skin, the blood-brain barrier, is influenced by its physicochemical properties and characteristics of the biomembrane (Shinoda, 2016; Di Meo et al., 2016). Biomembranes contain cellular material in a closed space and provide a dynamic interface for interaction with the extracellular milieu. However, from a pharmaceutical perspective, biomembranes can also act as a barrier to drug delivery. Knowledge of these influences can provide us with a capability to localize drugs in specific body compartments by modifying the delivery systems, altering the route of administration, and incorporating the compartment-specific targeting moieties. With the goal of promoting drug permeation across a biomembrane, these techniques and approaches essentially hinge on the modulation of the interaction between the drug and the bilayer. This special issue is a collection of articles describing the state of the art pertaining to the use of biocompatible polymeric nanoparticles as drug carriers of bioactive compounds. The research articles discuss the in vivo fate of polymeric nanosystems in relation to the unique characteristics of the tumor microenvironment. A couple of other articles discuss the delivery of drugs through the cutaneous route.
Torres et al. reviewed the nature of biobarriers and strategies to overcome them for the delivery of anticancer drugs. Specifically, the authors described nanocarriers composed of stimuli-responsive and self-assembling amphiphilic block copolymers to modulate the release of the payload. Exemplified by polylysine-cholate/PEG matrix to carry doxorubicin and deliver by pH stimuli (Zhu et al., 2012), such polymers are biocompatible and their compositions are tunable to match desired circulation persistence and target-oriented surface functionalization. Drug delivery by magnetic stimuli is another approach investigated by Li et al. The researchers employed an external magnetic field to induce localization of zolendronate-PLGA nanoparticles carrying superparamagnetic iron oxide in joints of a mouse model of osteolysis. They loaded these nanoparticles with curcumin to create dual-targeted nanoparticles and showed inhibition of NF-κB signaling and enhanced efficacy against polyethylene-induced osteolysis. Extending the application of stimuli-driven delivery of drugs, Oddone et al. engaged reactive oxygen species (ROS)-responsive mPEG-thioketal-melphalan prodrug for the potential treatment of glioblastoma. Although no in vivo efficacy studies were conducted, the investigators characterized the delivery system and tested it in cell culture. Thioketal linkage is sensitive to ROS and cleavage of thioketal bond releases melphalan from the micellar assembly of the drug-polymer conjugate. Because ROS levels are higher in cancer cells than in normal cells, such systems are expected to show selective cytotoxicity against cancer cells. In addition, the use of concomitant radiotherapy can enhance the anticancer effect of mPEG-thioketal-melphalan prodrug by increasing ROS levels.
For topical drug delivery, the skin acts as a biological barrier. It is the largest organ of our body and its various strata limit the permeation of substances. Here, Tumpara et al. proposed a simple topical delivery to replace traditionally employed intravenous infusion of α1-antitrypsin (AAT) protein (molecular weight ∼52 kDa). They evaluated transepidermal passive diffusion of AAT from buffered solution using 3D epidermis inserts reconstructed from primary human epidermal keratinocytes. The researchers reported that AAT was freely diffused across the epidermis layers in a concentration- and time-dependent manner. More importantly, there was no damage to the keratinocyte layers and AAT application reduced the inflammatory markers (IL-1α and IL-18) induced by LPS treatment. Given the simplicity of the approach, this cutaneous delivery of AAT warrants in vivo testing, as it will provide a new administration route to treat patients with inherited AAT deficiency.
One of the challenges in skin delivery is the real-time monitoring of payload after application. Snoswell et al. proposed a novel method to monitor cutaneous drug delivery. This method is based on motion capture and shows promise both as a training tool and as a means to assist in the development of skin drug delivery technologies. The investigators demonstrated the use of a “pen-type” applicator to capture the motion of Na-fluorescein-loaded elongated microparticles within ex vivo porcine skin samples; the permeation of microparticles was evaluated as a function of fluorescence, azimuth angle of application, frequency, and time. Since this is a non-invasive technique, it can be translated in humans to monitor drug delivery and detect mechanical differences among individuals, especially when significant variations in pharmacological outcomes or clinical efficacy are expected.
In summary, the articles in this special issue provide an overview of challenges posed by biological membranes and a few strategies to overcome them. The approaches described herein have in common the requisites to avoid the permanent destabilization of biobarriers to improve drug permeation. Encapsulation or complexation of drugs within polymeric micro/nanocarriers is one of many strategies to achieve this goal, mainly for parenteral administration (Maghrebi et al., 2019; Yari et al., 2020; Voci et al., 2021); a few such nanoformulations are now approved for clinical application or are under investigation (Mura et al., 2019; Jena et al., 2020; Sofias et al., 2021). Techniques and innovative formulations have also been developed to increase the skin delivery of the bioactives (Aich et al., 2021; Amani et al., 2021; Kaur and Kesharwani. 2021; Roberts et al., 2021). Although clinical development of drug and formulation products of nanomedicine class is still in its infancy (He et al., 2019), the guest editors opine that the advances in new biocompatible polymeric compositions and innovative non-invasive monitoring techniques will hasten the clinical translation of this research.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AichK.SinghT.DangS. (2021). Advances in Microneedle-Based Transdermal Delivery for Drugs and Peptides. Drug Deliv. Transl. Res.11, 2326–2343. 10.1007/s13346-021-01056-8
2
AmaniH.ShahbaziM. A.D'AmicoC.FontanaF.AbbaszadehS.SantosH. A. (2021). Microneedles for Painless Transdermal Immunotherapeutic Applications. J. Control Release.330, 185–217. 10.1016/j.jconrel.2020.12.019
3
Di MeoF.FabreG.BerkaK.OssmanT.ChantemargueB.PaloncýováM.et al (2016). In Silico pharmacology: Drug Membrane Partitioning and Crossing. Pharmacol. Res.111, 471–486. 10.1016/j.phrs.2016.06.030
4
HeH.LiuL.MorinE. E.LiuM.SchwendemanA. (2019). Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures. Acc. Chem. Res.52, 2445–2461. 10.1021/acs.accounts.9b00228
5
JenaL.McErleanE.McCarthyH. (2020). Delivery across the Blood-Brain Barrier: Nanomedicine for Glioblastoma Multiforme. Drug Deliv. Transl. Res.10, 304–318. 10.1007/s13346-019-00679-2
6
KaurH.KesharwaniP. (2021). Advanced Nanomedicine Approaches Applied for Treatment of Skin Carcinoma. J. Control Release.337, 589–611. 10.1016/j.jconrel.2021.08.003
7
MaghrebiS.PrestidgeC. A.JoyceP. (2019). An Update on Polymer-Lipid Hybrid Systems for Improving Oral Drug Delivery. Expert Opin. Drug Deliv.16, 507–524. 10.1080/17425247.2019.1605353
8
MuraS.FattalE.NicolasJ. (2019). From Poly(alkyl Cyanoacrylate) to Squalene as Core Material for the Design of Nanomedicines. J. Drug Target.27, 470–501. 10.1080/1061186X.2019.1579822
9
RobertsM. S.CheruvuH. S.MangionS. E.AlinaghiA.BensonH. A. E.MohammedY.et al (2021). Topical Drug Delivery: History, Percutaneous Absorption, and Product Development. Adv. Drug Deliv. Rev.177, 113929. Epub 2021 Aug 14. 10.1016/j.addr.2021.113929
10
ShinodaW. (2016). Permeability across Lipid Membranes. Biochim. Biophys. Acta1858, 2254–2265. 10.1016/j.bbamem.2016.03.032
11
SofiasA. M.CombesF.KoschmiederS.StormG.LammersT. (2021). A Paradigm Shift in Cancer Nanomedicine: from Traditional Tumor Targeting to Leveraging the Immune System. Drug Discov. Today26, 1482–1489. 10.1016/j.drudis.2021.02.017
12
VociS.FrestaM.CoscoD. (2021). Gliadins as Versatile Biomaterials for Drug Delivery Applications. J. Control Release329, 385–400. 10.1016/j.jconrel.2020.11.048
13
YariH.GaliH.AwasthiV. (2020). Nanoparticles for Targeting of Prostate Cancer. Curr. Pharm. Des.26, 5393–5413. 10.2174/1381612826666200721001500
14
ZhuL.ZhaoL.QuX.YangZ. (2012). pH-Sensitive Polymeric Vesicles from Coassembly of Amphiphilic Cholate Grafted poly(L-Lysine) and Acid-Cleavable Polymer-Drug Conjugate. Langmuir28, 11988–11996. 10.1021/la3015767
Summary
Keywords
biobarriers, polymeric nanoparticles, drug delivery, BBB, skin
Citation
Awasthi V, Bulotta S and Cosco D (2021) Editorial: Bypassing the Biological Barriers by Means of Biocompatible Drug Delivery Systems. Front. Pharmacol. 12:801383. doi: 10.3389/fphar.2021.801383
Received
25 October 2021
Accepted
02 November 2021
Published
24 November 2021
Volume
12 - 2021
Edited and reviewed by
Salvatore Salomone, University of Catania, Italy
Updates
Copyright
© 2021 Awasthi, Bulotta and Cosco.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vibhudutta Awasthi, vawasthi@ouhsc.edu; Stefania Bulotta, bulotta@unicz.it; Donato Cosco, donatocosco@unicz.it
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.